Related Experiment Video
Updated: Nov 29, 2025

An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse
Published on: September 12, 2018
Durvalumab-associated vasculitis presenting as 'the blue toe syndrome'
Shivangi Gupta1, Dan Xu2,3, Jane Hadfield4
1Curtin Medical School, Faculty of Health Sciences, Curtin University Bentley Campus, Perth, Western Australia, Australia.
Durvalumab, a checkpoint inhibitor, can cause rare immune-related side effects. This case highlights acral vasculitis, presenting as blue toe syndrome, associated with prolonged durvalumab use in a non-small-cell lung cancer patient.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Durvalumab is an immune checkpoint inhibitor targeting PD-L1, used in non-small-cell lung cancer.
- While effective, durvalumab can cause immune-related adverse events like pneumonitis and colitis.
- Acral vasculitis is a rare but serious potential side effect.
More Related Videos
09:29Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
08:16High-Resolution Three-Dimensional Imaging of the Footpad Vasculature in a Murine Hindlimb Gangrene Model
Published on: March 16, 2022
Related Concept Videos
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Endocarditis II: Clinical Features of Infective Endocarditis
Assessment of the Cardiovascular System III: Palpation
Jugular Venous Pressure (JVP) Measurement
Position the patient at a thirty- to forty-five-degree angle or in a semi-fowler's position. Look for the highest point of pulsation in the internal jugular vein and measure the vertical distance to the angle of Loius or sternal angle. A normal JVP is 3-4 cm above...
Disorders of the Autonomic Nervous System
Raynaud's disease, also known as Raynaud's...
Vascular Spasm